TRENDING TOPICS
3286 articles found for "investing"
Disney's theme parks, resorts, and cruise division posted a record $10 billion in Q1 FY2026 revenue, generating 71% of the company's total operating income.
ConocoPhillips reported Q4 adjusted earnings of $1.02 per share as lower oil prices cut into profits, but the Marathon Oil merger is delivering double the expected synergies.
Jamie Dimon warns 'when you see one cockroach, there are probably more' as the $3.4 trillion private credit market faces rising defaults, hidden risks, and comparisons to pre-2008 excess.
Eli Lilly reported Q4 revenue of $19.3 billion, up 43% year-over-year, as Zepbound captured 64% of branded anti-obesity prescriptions and the company guided for $80-83 billion in 2026 sales.
Wistron's $761 million Fort Worth factory is set to begin volume production of Nvidia AI supercomputers in the first half of 2026, marking the first time these systems will be manufactured entirely on US soil.
Broadcom's AI chip backlog hit $73 billion with Q1 FY2026 AI revenue guidance of $8.2 billion, while a multi-year OpenAI partnership valued at over $100 billion positions the chipmaker as Nvidia's most formidable rival.
Caterpillar shares reach an all-time high of $723.32 as AI data center power orders fuel a record $51 billion backlog and the company's Power & Energy segment becomes its fastest-growing business.
South Korea's ruling party has pledged to ratify its US trade agreement by end of February after President Trump threatened to raise tariffs from 15% to 25% on automobiles, pharmaceuticals, and other key exports.
Ubiquiti reports record Q2 FY2026 revenue of $814.9 million, up 36% year-over-year, with adjusted EPS of $3.88 crushing the $3.08 consensus estimate as enterprise networking demand surges.
Bitcoin plunges to $60,033 in early Friday trading, breaching the critical $60,000 support level for the first time since October 2024 as forced liquidations exceed $2.7 billion and institutional demand reverses.
Centene reports Q4 2025 earnings with analysts expecting a loss of $1.25 per share despite 18% revenue growth, as soaring medical costs and Medicaid redeterminations squeeze the nation's biggest government health plan manager.
Novo Nordisk shares plunge 17% after the Ozempic maker warns of a 5% to 13% sales decline in 2026, while rival Eli Lilly guides for 27% growth — marking a stunning divergence in the $150 billion obesity drug market.